Fig. 3: Ovarian cancer co-cultures immune study of effector lymphocytes response to the combination treatment.
3.5 × 105 cells of HUSOV4, HUSOV6, HUSOV9, HUSOV10, and HUSOV13 ovarian cancer tumor digests were plated and incubated for 24 h. Then, samples were treated with their respective day 14 expanded autologous TILs at (3:1) effector to target ratio. In addition, 100vp/cell of either Ad5/3-E2F-d24 virus or Ad5/3-E2F-d24-vIL2 were added to the co-cultures. Autologous TILs treatment as a monotherapy was used as a control of the assay. Co-cultures were incubated at 37 °C and cells were harvested for flow cytometry analyses on day 6. Percentage of (A) CD4+ T cells, (B) granzyme B CD4+ T cells, and (C) PD-1 + CD4+ T cells in day 6 co-cultures. D Levels of CD8+ T cells, E granzyme B CD8+ T cells, and (F) PD-1 + CD8+ T cells in the treated ovarian cancer digests. Percentage of (G) CD56+ cells, (H) granzyme B CD56+ cells, and (I) PD-1 + CD56+ cells in day 6 treated co-cultures. Data sets were analysed for statistical significance by unpaired T test with Welch’s correction and presented as mean +− SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
